This project will test the hypothesis that hepatocellular free fatty acid levels are an important determinant of blood pressure. The hypothesis predicts that visceral or abdominal obesity is strongly associated with hypertension because visceral fat cells release their fatty acids into the portal circulation, causing a marked increase in hepatic fatty acid content. By contrast, individuals with lower body obesity, whose risk for hypertension is low, should have lower hepatic fatty acid levels. Preliminary data from our laboratory demonstrate that infusion of long chain free fatty acids into rats results in elevated blood pressure and increased hepatic free fatty acid levels. This project will characterize the hypertension associated with fatty acid infusion and determine whether hepatic fatty acid content is a significant determinant of blood pressure. Conscious, instrumented rats will be studies. Infusions of fatty acid solution or vehicle into the systemic and portal circulations will be assessed with regard to their effects on blood pressure. The systemic and regional hemodynamic responses to fatty acid hypertension will be determined and the associated renal and hormonal changes will be measured. Dose response curves to establish the relationship between amount of fatty acid infused and pressor response will be determined for both systemic and portal infusions. In separate experiments, plasma and tissue levels of fatty acids associated with the hypertensive response will be determined. Infusions of different long and medium chain fatty acids will be performed to assess whether saturation or chain length of the infused fatty acid influences the pressor response. Long term infusions of fatty acids will then be performed to ascertain whether chronic hypertension can be induced. In order to determine the relationship between fatty acids and insulin resistance, in vivo studies using the minimal model of insulin sensitivity will be undertaken. Insulin sensitivity during fatty acid infusion will be compared with sensitivity during vehicle infusion. In vitro studies will be performed to assess the effects of fatty acids on vascular reactivity. In addition, vessels from animals treated in vivo with fatty acid infusion will be compared to vessels from control animals. The effect of fasting in lean and obese animals on hepatic fatty acid content and blood pressure will be determined. Fatty acid infusions and etomoxir will be used to maintain hepatic fatty acid levels in the range seen in fed animals during a three day fast. These studies will determine whether maintaining hepatic fatty acid levels prevents the decrease in blood pressure and the increase in insulin sensitivity which normally occurs with fasting. Nicotinin acid will be used to decrease hepatic FFA content in obese, hypertensive rats, and its effects on blood pressure and hepatic FFA content will be determined. These studies should characterize the pressor effects fatty acids and provide insight into the role of fatty acids in the hypertension of abdominal obesity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL018575-23
Application #
6109435
Study Section
Project Start
1998-07-01
Project End
1999-06-30
Budget Start
Budget End
Support Year
23
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Rocchini, Albert P; Yang, John Q; Smith, Marla J et al. (2010) Serial changes in norepinephrine kinetics associated with feeding dogs a high-fat diet. J Clin Hypertens (Greenwich) 12:117-24
Kamal, Mohamed A; Keep, Richard F; Smith, David E (2008) Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity. Drug Metab Pharmacokinet 23:236-42
Duan, Sheng Zhong; Ivashchenko, Christine Y; Whitesall, Steven E et al. (2007) Direct monitoring pressure overload predicts cardiac hypertrophy in mice. Physiol Meas 28:1329-39
Hu, Yongjun; Shen, Hong; Keep, Richard F et al. (2007) Peptide transporter 2 (PEPT2) expression in brain protects against 5-aminolevulinic acid neurotoxicity. J Neurochem 103:2058-65
Ennis, Steven R; Keep, Richard F (2007) Effect of sustained-mild and transient-severe hyperglycemia on ischemia-induced blood-brain barrier opening. J Cereb Blood Flow Metab 27:1573-82
Shen, Hong; Ocheltree, Scott M; Hu, Yongjun et al. (2007) Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos 35:1209-16
Xiang, Jianming; Chiang, Pei-Pei; Hu, Yongjun et al. (2006) Role of PEPT2 in glycylsarcosine transport in astrocyte and glioma cultures. Neurosci Lett 396:225-9
Ennis, S R; Keep, R F (2006) Effects of 2,4-dinitrophenol on ischemia-induced blood-brain barrier disruption. Acta Neurochir Suppl 96:295-8
Carello, Katari A; Whitesall, Steven E; Lloyd, Mary C et al. (2006) Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol 290:H209-16
Xiang, Jianming; Hu, Yongjun; Smith, David E et al. (2006) PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res 1122:18-23

Showing the most recent 10 out of 291 publications